Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis
Tóm tắt
We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1).
Glucose production was investigated in isolated hepatocytes and during pancreatic clamps in healthy rats. Chronic treatments on C57BL/6J, db/db, high-fat fed mice, and rats were performed to understand glucose metabolism and insulin sensitivity.
In isolated hepatocytes, teglicar concentration dependently reduced ketone bodies and glucose production up to 72 and 50%, respectively. In rats, teglicar reduced the endogenous glucose production (−62%) without affecting peripheral glucose utilization. Heart 2-[3H]deoxyglucose uptake in mice was also not affected, confirming in vivo the drug selectivity toward L-CPT1. Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced postabsorptive glycemia (−38%), water consumption (−31%), and fructosamine (−30%). Such antidiabetic activity was associated with an improved insulin sensitivity assessed by the insulin tolerance test. A significant 50% increase in hepatic triglyceride content (HTGC) was found, although plasma alanineaminotransferase was not altered. In addition, long-term teglicar administration to high-fat fed C57BL/6J mice normalized glycemia (−19%) and insulinemia (−53%). Long-term teglicar administration (30 days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced basal glycemia (−20%, ns), reduced basal insulin levels by 60%, doubled triglycerides, and increased free-fatty acids (+53%). HTGC was markedly increased, but liver and peripheral insulin sensitivity assessed by hyperinsulinemiceuglycemic clamp were not affected.
Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.
Từ khóa
Tài liệu tham khảo
Basu, 2004, Both fasting glucose production and disappearance are abnormal in people with “mild” and “severe” type 2 diabetes, Am J Physiol Endocrinol Metab, 287, E55, 10.1152/ajpendo.00549.2003
Boden, 2001, Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus, Am J Physiol Endocrinol Metab, 280, E23, 10.1152/ajpendo.2001.280.1.E23
DeFronzo, 1992, Pathogenesis of NIDDM. A balanced overview, Diabetes Care, 15, 318, 10.2337/diacare.15.3.318
Proietto, 2004, Molecular mechanisms of increased glucose production: identifying potential therapeutic targets, J Investig Med, 52, 389, 10.1136/jim-52-06-33
McCormack, 2001, Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy, Curr Pharm Des, 7, 1451, 10.2174/1381612013397393
Mandarino, 1984, Mechanism of hyperglycemia and response to treatment with an inhibitor of fatty acid oxidation in a patient with insulin resistance due to antiinsulin receptor antibodies, J Clin Endocrinol Metab, 59, 658, 10.1210/jcem-59-4-658
Ratheiser, 1991, Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus, Metabolism, 40, 1185, 10.1016/0026-0495(91)90214-H
Hübinger, 1997, Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM, Horm Metab Res, 29, 436, 10.1055/s-2007-979072
Bajaj, 2004, Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes, J Clin Endocrinol Metab, 89, 4649, 10.1210/jc.2004-0224
Boden, 2001, Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes, Diabetes, 50, 810, 10.2337/diabetes.50.4.810
Walter, 1976, Pyruvate carboxylase: intracellular localization and regulation, Gluconeogenesis: Its Regulation in Mammalian Species, 239
McGarry, 1997, The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis, Eur J Biochem, 244, 1, 10.1111/j.1432-1033.1997.00001.x
Loftus, 2000, Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors, Science, 288, 2379, 10.1126/science.288.5475.2379
Hu, 2003, Hypothalamic malonyl-CoA as a mediator of feeding behavior, Proc Natl Acad Sci USA, 100, 12624, 10.1073/pnas.1834402100
Obici, 2003, Minireview: nutrient sensing and the regulation of insulin action and energy balance, Endocrinology, 144, 5172, 10.1210/en.2003-0999
Bressler, 1989, Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction, Life Sci, 44, 1897, 10.1016/0024-3205(89)90401-3
Dobbins, 2001, Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats, Diabetes, 50, 123, 10.2337/diabetes.50.1.123
Giannessi, 2003, Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity, J Med Chem, 46, 303, 10.1021/jm020979u
Anderson, 1995, Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors, J Med Chem, 38, 3448, 10.1021/jm00018a003
Deems, 1998, Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys, Am J Physiol, 274, R524
Anderson, 1998, Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?, Curr Pharm Des, 4, 1
Oakes, 2001, Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability, Diabetes, 50, 1158, 10.2337/diabetes.50.5.1158
Mauvais-Jarvis, 2000, A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes, Diabetes, 49, 2126, 10.2337/diabetes.49.12.2126
Berry, 1991, Isolated Hepatocytes Preparation, Properties and Applications
Rigoulet, 1987, Stimulation by glucose of gluconeogenesis in hepatocytes isolated from starved rats, Biochem J, 245, 661, 10.1042/bj2450661
Kraegen, 1985, Dose-response curves for in vivo insulin sensitivity in individual tissues in rats, Am J Physiol, 248, E353
Lazarow, 1981, Assay of peroxisomal beta-oxidation of fatty acids, Methods Enzymol, 72, 315, 10.1016/S0076-6879(81)72021-4
Randle, 1963, The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, 1, 785, 10.1016/S0140-6736(63)91500-9
Randle, 1998, Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years, Diabetes Metab Rev, 14, 263, 10.1002/(SICI)1099-0895(199812)14:4<263::AID-DMR233>3.0.CO;2-C
Schmidt-Schweda, 2000, First clinical trial with etomoxir in patients with chronic congestive heart failure, Clin Sci (Lond), 99, 27, 10.1042/CS19990235
Seppälä-Lindroos, 2002, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men, J Clin Endocrinol Metab, 87, 3023, 10.1210/jcem.87.7.8638
Grefhorst, 2005, Acute hepatic steatosis in mice by blocking β-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production, Am J Physiol Gastrointest Liver Physiol, 289, G592, 10.1152/ajpgi.00063.2005
Duivenvoorden, 2005, Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity, J Lipid Res, 46, 988, 10.1194/jlr.M400505-JLR200
Buettner, 2004, Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis, Am J Physiol Endocrinol Metab, 286, E828, 10.1152/ajpendo.00453.2003
Heijboer, 2005, Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice, J Lipid Res, 46, 582, 10.1194/jlr.M400440-JLR200
Wendel, 2010, Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity, Diabetes, 1321
Obici, 2003, Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production, Nat Med, 9, 756, 10.1038/nm873
Coccurello, 2010, Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice, Psychopharmacology (Berl), 210, 85, 10.1007/s00213-010-1820-0
Bennett, 2004, Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency, Mol Genet Metab, 82, 59, 10.1016/j.ymgme.2004.02.004
Prip-Buus, 2001, Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community, Mol Genet Metab, 73, 46, 10.1006/mgme.2001.3176
Stoler, 2004, Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation, J Inherit Metab Dis, 27, 679, 10.1023/B:BOLI.0000042979.42120.55